11:57 AM EST - Oncolytics Biotech Inc. : Announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1. Consistent with the safety run-in with patients receiving pelareorep and Tecentriq®, Cohort 1 demonstrated widespread viral replication in the majority of tumors with the creation of a pro-inflammatory effect in the tumor microenvironment. No negative effects to healthy tissue were noted. Oncolytics Biotech Inc.
shares T.ONC are trading up 50 cents at $2.17.
